These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8743027)

  • 1. Hypertension, coronary artery and cerebrovascular diseases in the population. Has epidemiology changed in the last decades?
    Pessina AC; Serena L; Semplicini A
    Clin Exp Hypertens; 1996; 18(3-4):363-70. PubMed ID: 8743027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of hypertension in patients with a metabolic disorder].
    Dal Palù C; Semplicini A
    Ann Ital Med Int; 1995 Oct; 10 Suppl():130S-132S. PubMed ID: 8562259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality and morbidity in relation to systolic blood pressure in two populations with different management of hypertension: The Study of Men Born in 1913 and the Multifactorial Primary Prevention Trial.
    Samuelsson OG; Wilhelmsen LW; Svärdsudd KF; Pennert KM; Wedel H; Berglund GL
    J Hypertens; 1987 Feb; 5(1):57-66. PubMed ID: 3584964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of cardiovascular morbidity and mortality in hypertension: benefits of blood pressure reduction and cholesterol lowering.
    MacMahon S
    Postgrad Med J; 1989; 65 Suppl 1():S55-7. PubMed ID: 2695910
    [No Abstract]   [Full Text] [Related]  

  • 5. Changes in dietary habits, cardiovascular risk factors and mortality in Japan.
    Ueshima H
    Acta Cardiol; 1989; 44(6):475-7. PubMed ID: 2626912
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of antihypertensive drug treatment on the incidence of cardiovascular morbidity and mortality in mild arterial hypertension].
    Tomov I
    Vutr Boles; 1985; 24(6):39-47. PubMed ID: 3913145
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of health behaviors related to hypertension in three blood pressure treatment groups: the Minnesota Heart Health Program.
    Nothwehr F; Elmer P; Hannan P
    Prev Med; 1994 May; 23(3):362-8. PubMed ID: 8078858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on prevention and medical education for the 1990s.
    Nickens HW; Petersdorf RG
    Am J Prev Med; 1990; 6(2 Suppl):1-5. PubMed ID: 2383407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of cardiovascular diseases: current perspectives.
    Kuller LH
    Am J Epidemiol; 1976 Oct; 104(4):425-96. PubMed ID: 788505
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of cardiovascular events in elderly people.
    Andrawes WF; Bussy C; Belmin J
    Drugs Aging; 2005; 22(10):859-76. PubMed ID: 16245959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension as a risk factor for cardiac events--epidemiologic results of long-term studies.
    Kannel WB
    J Cardiovasc Pharmacol; 1993; 21 Suppl 2():S27-37. PubMed ID: 7692148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of cost-effectiveness of drug therapy: a review of the treatment of hypertension.
    Moulds RF
    Med J Aust; 1990 Aug; 153(S1):S4-6. PubMed ID: 2116584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent trends in the mortality and morbidity of cardiovascular diseases.
    Chen AJ
    Ann Acad Med Singap; 1980 Oct; 9(4):411-5. PubMed ID: 7247325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of primary and secondary prevention on morbidity and mortality of ischemic cardiopathy].
    Posadas-Romero C
    Arch Cardiol Mex; 2002; 72 Suppl 1():S167-70. PubMed ID: 12001839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Arterial hypertension and cardiovascular risk. Epidemiological studies, trials and therapeutic implications].
    Iannetti M; Vallebona A; Caponnetto S
    Minerva Cardioangiol; 1991 Oct; 39(10):367-74. PubMed ID: 1803282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience).
    Kannel WB
    Am J Cardiol; 1996 Feb; 77(6):6B-11B. PubMed ID: 8848993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The relevance of mortality due to circulatory system diseases in Spain].
    Banegas Banegas JR; Villar Alvarez F; Martín Moreno JM; Rodríguez Artalejo F; González Enríquez J
    Rev Clin Esp; 1992 Apr; 190(6):321-7. PubMed ID: 1598433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
    Milne RJ; Vander Hoorn S; Jackson RT
    Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing pattern of cardiovascular diseases in China.
    Yao C; Wu Z; Wu Y
    World Health Stat Q; 1993; 46(2):113-8. PubMed ID: 8303905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.